2021 Mira Pecheva
Establishing inhibition of MMP-14 as a viable therapeutic in Dupuytren’s Disease
Dupuytren’s disease therapy: MMP-14 enzyme blocking
Dupuytren’s disease (DD) is characterised by thickening of a structure present in all hands (the palmar fascia), affecting hand use, with psychological, family and employment effects. 2 million people have DD in the UK. Treatment is through surgery, but the disease can return. The enzyme MMP-14 is associated with DD severity and recurrence. This project will outline the role of MMP-14 in DD. In the near-term, patients can donate tissue excised as part of their treatment, playing an active role in research. The translation of this research into therapy will provide long-term non-surgical treatment. To read the full report
2019 Gurdas Singh
Choosing cost-effective treatments for Dupuytren’s disease
Dupuytren’s disease is a common condition in which scar-like tissue forms under the palm skin. This forms cords of tissue that pull the fingers into the palm and limits function. It typically occurs in men over 50. In the UK, about 20% of people over 65 have some form.
Decision-analytic mathematic models estimate the expected costs and effectiveness of different treatments. They can account for people then needing further treatment, and so may provide a more realistic way to understand the impact of treatments in ways that can inform clinical and commissioning decisions. To read the full report
2017 Thomas Layton
Defining the myofibroblast phenotype in Dupuytren’s disease
Identifying and exploring novel myofibroblast markers in Dupuytren’s Disease.
Dupuytren’s disease (DD) is a fibrotic disorder of the hand affecting 4% of the UK population. It leads to impairment of hand function as the fingers curl irreversibly into the palm. The cells responsible for the deposition of the excessive tissue and contraction are myofibroblasts. However, we still lack a clear understanding of these cells and this has hampered efforts to develop new treatments. We aim to better understand the myofibroblast in DD by defining genes specific to these cells compared to control cells from the same patients, and subsequently exploring their function. To read the full report
2015 Hawys Lloyd-Hughes
Improving the Qualitative and Quantitative Outcomes of Dupuytren’s Disease
To read the full report